Abstract
AbstractBackgroundFinding the correct drug dose for a specific condition is a key step in many treatments, and failing to do so can lead to deleterious consequences to patient health. Clinical protocols are derived from drug development phase prospective trials. While carefully designed, these often do not include all potential patients, comorbidities or clinical outcomes, ultimately leading to sub-optimal dosing policies. Observational datasets provide real-world information that cannot be substituted with data collected in a controlled environment. Several published methodologies have applied observational datasets for the development of clinical protocols, however these are only applicable whenever these datasets are varied and complete. Often, clinical observational datasets do not comply with these requirements. Computational methods can and should exploit field knowledge to address weaknesses associated with clinical observational data.MethodsThis paper proposes IDoser, a core dosing model that links drug dose to relevant covariates via a set of coefficients, and includes a loss function to codify needed assumptions and requirements. Coordinate descent is used to obtain a fitted model with minimal loss. The loss function is also used to measure performance when validating the model with unseen data. Our proposal is validated using the case of follicle stimulating hormone (FSH) dosing for controlled ovarian stimulation (COS).ResultsThe proposed Individualized Doser (IDoser) achieved significant improvements when loss values were compared to observed clinical practice and a selected literature benchmark and during the validation phase.ConclusionsThis methodology constitutes a simple but effective method to bridge the gap between current clinical dosing policies and gold policies based on the true underlying and often unknown dose-response functions.
Publisher
Cold Spring Harbor Laboratory
Reference44 articles.
1. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials
2. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles
3. Arce, J.C. , Klein, B.M. , Erichsen, L. , 2016. Using amh for determining a stratified gonadotropin dosing regimen for IVF/ICSI and optimizing outcomes. Anti-Mullerian Hormone: Biology, Role in Ovarian Function and Clinical Significance, 83–102.
4. From Real‐World Patient Data to Individualized Treatment Effects Using Machine Learning: Current and Future Methods to Address Underlying Challenges
5. Bica, I. , Jordon, J. , 2020. Estimating the Effects of Continuousvalued Interventions using Generative Adversarial Networks arXiv:arXiv:2002.12326v2.